ETC-159 is primarily investigated for its potential in cancer therapy, particularly in targeting Wnt signaling pathways that are often dysregulated in various cancers. It shows promise in inhibiting tumor growth and progression, especially in colorectal and pancreatic cancers, where Wnt signaling plays a critical role. Additionally, ETC-159 is being explored for its efficacy in combination therapies, enhancing the effectiveness of other anticancer drugs. Its ability to selectively target cancer cells while sparing normal tissues makes it a valuable candidate for precision medicine approaches. Research is also ongoing to evaluate its application in treating other diseases linked to abnormal Wnt signaling, such as fibrosis and certain neurodegenerative disorders.